Abstract:Objective:The selective criteria of orphan drugs in medical insurance reimbursement list were studied by using multiple criteria decision analysis(MCDA) in China.Methods:A broad spectrum of stakeholders,including 61 government officials,medical insurance managers,pharmaceutical Co.staff and academia were surveyed by questionnaires.SPSS was applied to conduct the statistical analysis on the mean and standard deviation.Four groups of stakeholders were tested by Kendall rank consistency.Results:The top 3 factors influenced on high price of orphan drugs were low number of rare diseases(RD) cases,high cost of R&D(research and development) and high cost of production.From the 8 selective criteria for selecting RD orphan drugs,the order of importance was as follows:efficacy,safety,and severity of disease,the affordability of insurance budget and the equity of treatment.The results of the study in China were compared with that in Bosnia and Herzegovina,Poland,Czech,Greece and Hungary.It found that the government officials and medical insurance managers in China were paid more attention on the severity of RD,clinical efficacy,drug safety and the affordability of insurance budget.The unmet need and the preference of patients seemed not as importance as the other attributed.The results were slightly different from that in foreign countries.Conclusion:In China,the prevention and control policy of RD had been started,and the multi-channel financing mechanism were emerging.However,the recognition of RD and the preference for oatients were still not enough.

The Selective Conditions of Orphan Drugs by Using Multiple Criteria Decision Analysis in China